Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad study

Karim Amrane, Luca Campedel, Fabien Moinard-Butot, Mathilde Gout, Hakim Mahammedi, Mostefa Bennamoun, Tressie Herrmann, Pierre-Etienne Gabriel, Damien Pouessel, Matthieu Roulleaux-Dugage, Constance Thibault, Mathilde Cancel, Aude Flechon, Olivier Huillard, Baptiste Abbar, Delphine Borchiellini, Louis Doublet, Laëtitia Augusto-Pelegrin, Elouen Boughalem, Pierre Cornillon, Clément Dumont, Philippe Barthélémy

Open source

DOI: 10.1007/s00262-026-04421-z
Published: 2026-05-24
Container: Cancer Immunology, Immunotherapy
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s00262-026-04421-z,
  title = {Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad study},
  author = {Karim Amrane and Luca Campedel and Fabien Moinard-Butot and Mathilde Gout and Hakim Mahammedi and Mostefa Bennamoun and Tressie Herrmann and Pierre-Etienne Gabriel and Damien Pouessel and Matthieu Roulleaux-Dugage and Constance Thibault and Mathilde Cancel and Aude Flechon and Olivier Huillard and Baptiste Abbar and Delphine Borchiellini and Louis Doublet and Laëtitia Augusto-Pelegrin and Elouen Boughalem and Pierre Cornillon and Clément Dumont and Philippe Barthélémy},
  year = {2026},
  journal = {Cancer Immunology, Immunotherapy},
  doi = {10.1007/s00262-026-04421-z},
  url = {https://doi.org/10.1007/s00262-026-04421-z}
}

RIS

TY  - JOUR
TI  - Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad study
AU  - Karim Amrane
AU  - Luca Campedel
AU  - Fabien Moinard-Butot
AU  - Mathilde Gout
AU  - Hakim Mahammedi
AU  - Mostefa Bennamoun
AU  - Tressie Herrmann
AU  - Pierre-Etienne Gabriel
AU  - Damien Pouessel
AU  - Matthieu Roulleaux-Dugage
AU  - Constance Thibault
AU  - Mathilde Cancel
AU  - Aude Flechon
AU  - Olivier Huillard
AU  - Baptiste Abbar
AU  - Delphine Borchiellini
AU  - Louis Doublet
AU  - Laëtitia Augusto-Pelegrin
AU  - Elouen Boughalem
AU  - Pierre Cornillon
AU  - Clément Dumont
AU  - Philippe Barthélémy
PY  - 2026
JO  - Cancer Immunology, Immunotherapy
DO  - 10.1007/s00262-026-04421-z
UR  - https://doi.org/10.1007/s00262-026-04421-z
ER  -

APA

Amrane, K., Campedel, L., Moinard-Butot, F., Gout, M., Mahammedi, H., Bennamoun, M., Herrmann, T., Gabriel, P., Pouessel, D., Roulleaux-Dugage, M., Thibault, C., Cancel, M., Flechon, A., Huillard, O., Abbar, B., Borchiellini, D., Doublet, L., Augusto-Pelegrin, L., Boughalem, E., Cornillon, P., Dumont, C., & Barthélémy, P. (2026). Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad study. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04421-z

Source records

crossref · retrieved 2026-09-26T06:25:11.990Z